Understanding polycystic ovarian syndrome pathogenesis: An updated of its genetic aspects

Journal of Endocrinological Investigation

Volumn 34, Issue 8, 2011, Pages 630-644

  Calogero, A E ^a   Calabro V ^a   Catanuso, M ^a   Condorelli, R A ^a   La Vignera, S ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Adipose tissue genes; Gonadotropin genes; Insulin gene; PCOS; Steroidogenesis anzyme genes

Indexed keywords

ADIPONECTIN; ANDROGEN RECEPTOR; AROMATASE; CALPAIN 10; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 17; CYTOKINE; CYTOKINE RECEPTOR; FOLLISTATIN; GONADOTROPIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; LEPTIN RECEPTOR; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX HORMONE BINDING GLOBULIN; STEROID 21 MONOOXYGENASE; STEROID HORMONE;

ADIPOSE TISSUE; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC TRAIT; GONADOTROPIN RELEASE; HEREDITY; HORMONE METABOLISM; HUMAN; INSULIN RELEASE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; REVIEW;

ADIPOSE TISSUE; ANIMALS; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HORMONES; HUMANS; INFERTILITY, FEMALE; MALE; POLYCYSTIC OVARY SYNDROME; RECEPTOR, INSULIN; RECEPTORS, ANDROGEN; STEROID HYDROXYLASES;

EID: 84855465297     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7746     Document Type: Review

References (185)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89: 2745-9. (Pubitemid 38766360)
2. Escobar-Morreale HF, Roldán B, Barrio R, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000, 85: 4182-7. (Pubitemid 32055370)
3. Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997, 18: 774-800. (Pubitemid 28009567)
4. Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333: 853-61.
5. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005, 11: 631-43. (Pubitemid 41631312)
6. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, et al. Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11α influences hyperandrogenemia in patient with polycystic ovary syndrome. Fertil Steril 2000, 73: 735-41. (Pubitemid 30154112)
7. Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17-20) lyase promoters. Fertil Steril 2002, 77: 274-80. (Pubitemid 34086909)
8. Wang Y, Wu X, Cao Y, Yi L, Chen J. A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome. Fertil Steril 2006, 86: 223-6. (Pubitemid 43962960)
9. Urbanek M, Legro RS, Driscoll DA, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Nat Acad Sci (USA) 1999, 96: 8573-8. (Pubitemid 29354833)
10. San Millán JL, Sancho J, Calvo RM, Escobar-Morreale HF. Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 2001, 75: 797-802. (Pubitemid 32273517)
11. Calvo RM, Villuendas G, Sancho J, San Millán JL, Escobar-Morreale HF. Role of the follistatin gene in women with polycystic ovary syndrome Fertil Steril 2001, 75: 1020-3. (Pubitemid 32401685)
12. Gaasenbeek M, Powell BL, Sovio U, et al. Large-Scale analysis of the relationship between CYP11A promoter variation and polycystic ovarian syndrome. J Clin Endocrinol Metab 2004, 89: 2408-13. (Pubitemid 38619883)
13. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17α-hydroxylase/17-20 lyase): similarity with the gene for P450c21. DNA 1987, 6: 439-48. (Pubitemid 18085844)
14. Sharp L, Cardy AH, Cotton SC, Little J. CYP17 gene polymorphism: prevalence and associations with hormone levels and related factors. A HuGE: review. Am J Epidemiol 2004, 160: 729-40. (Pubitemid 39362210)
15. Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994, 79: 1686-92.
16. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c 17α as the cause of polycystic ovarian syndrome. Fertil Steril 1990, 53: 785-91. (Pubitemid 20180464)
17. Wickenheisser JK, Nelson-DeGrave VL, Quinn PG, McAllister JM. Increased cytochrome P450 17α-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol 2004, 18: 558-605.
18. Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Dysregulation of cytochrome P450 17α-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 1720-7. (Pubitemid 40464044)
19. Carey AH, Waterworth D, Patel K et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP 17. Hum Mol Genet 1994, 3: 1873-6. (Pubitemid 24310487)
20. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED et al. Polymorphism T->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999, 71: 431-5. (Pubitemid 29094117)
21. Gharani N, Waterworth DM, Williamson R, Franks S. 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovary. J Clin Endocrinol Metab 1996, 81: 4174. (Pubitemid 26380437)
22. Techatraisak K, Conway GS, Rumsby G. Frequency of a polymorphism in the regulatory region of the 17α.hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol 1997, 46: 131-4. (Pubitemid 27122156)
23. Witchel SF, Lee PA, Suda-Hartman M, Smith R, Hoffman EP. 17α-hydroxylase/17,20-lyase Dysregulation is not caused by mutations in the coding regions of CYP17. J Pediatr Adolesc Gynecol 1998, 11: 133-7. (Pubitemid 28429948)
24. Marszalek B, Lacinski M, Babych N, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001, 15: 123-8. (Pubitemid 32423252)
25. Echiburú B, Pérez-Bravo F, Maliqueo M, Sánchez F, Crisosto N, Sir-Petermann T. Polymorphism T→ C (-34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study. Metabolism 2008, 57: 1765-71.
26. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17, 20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995, 92: 10619-23.
27. Qin KN, Rosenfield RL. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol 1998, 145: 111-21. (Pubitemid 29003185)
28. Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988, 263: 3440-7. (Pubitemid 18072805)
29. Dunaif A, Xia J, Book C-B, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995, 96: 801-10.
30. Pandey AV, Miller WL. Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P45017. J Biol Chem 2005, 280: 13265-71. (Pubitemid 40517210)
31. Tee MK, Dong Q, Miller WL. Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis. Endocrinology 2008, 149: 2667-77. (Pubitemid 351574538)
32. Escobar-Morreale HF, San Millán JL, Smith RR, Sancho J, Witchel SF. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. Fertil Steril 1999, 72: 629-38. (Pubitemid 29475120)
33. Witchel SF, Aston CE. The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000, 13: 1315-7.
34. Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y. Hyperandrogenism in carriers of CYP21 mutations: the role of CYP21. Clin Endocrinol (Oxf) 2006, 64: 645-51. (Pubitemid 43775002)
35. Witchel SF, Kahsar-Miller M, Aston CE, White C, Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic syndrome and androgen excess. Fertil Steril 2005, 83: 371-5. (Pubitemid 40221791)
36. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A 1993, 90: 11673-7. (Pubitemid 24008701)
37. Takayama K, Fukaya T, Sasano H, et al. Immunohistochemical study of steroidogenesis and cell proliferation in polycystic ovarian syndrome. Hum Reprod 1996, 11: 1387-92. (Pubitemid 26335081)
38. Erickson GF, Hsueh AJW, Quigley ME, Rebar RW, Yen SS. Functional studies of aromatase activity in human granulose cells from normal and polycystic ovaries. J Clin Endocrinol Metab 1979, 49: 514-9. (Pubitemid 10231734)
39. Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod 1998, 4: 1-8. (Pubitemid 28109154)
40. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens or hypergonadotropic hypogonadism, multicystic ovaries and bone densitometry in childhood. J Clin Endocrinol Metab 1997, 82: 1739-45. (Pubitemid 127495177)
41. Gharani N, Waterworth DM, Batty S et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997, 6: 397-402. (Pubitemid 27116459)
42. Petry CJ, Ong KK, Michelmore KF, et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005, 20: 1837-43. (Pubitemid 40932365)
43. Petry CJ, Ong KK, Michelmore KF et al. Association between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. J Clin Endocrinol Metab 2006, 98: 199-206. (Pubitemid 43344249)
44. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988, 240: 327-30.
45. Carson-Jurica MA, Schrader WT, O'Malley BW. Steroid receptor family: structure and functions. Endocr Rev 1990, 11: 201-20. (Pubitemid 20182869)
46. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992, 12: 241-53.
47. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994, 22: 3181-6. (Pubitemid 24260654)
48. Legro RS, Shahbahrami M, Lobo RA, Kovaes BW. Size polymorphisms of the androgen-receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994, 83: 701-6. (Pubitemid 24153462)
49. Sawaya ME, Shalita AR. Androgen receptor polymorphism (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998, 3: 9-15. (Pubitemid 28352163)
50. Ibáñez L, Ong KK, Mongan N, et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003, 88: 3333-8. (Pubitemid 36877513)
51. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000, 85: 3484-8.
52. Kim JJ, Choung SH, Choi YM, Yoon SH, Kim SH, Moon SY. Androgen receptor gene CAG repeat polymorphism in women with polycystic ovary syndrome. Fertil Steril 2008, 90: 2318-23.
53. Jääskeläinen J, Korhonen S, Voutilainen R, Hippeläinen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil Steril 2005, 83: 1724-8. (Pubitemid 40824805)
54. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007, 3: 103-11. (Pubitemid 46146963)
55. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 161-5. (Pubitemid 34084686)
56. Liu Q, Hong J, Cui B et al. Androgen receptor gene CAG(n) trinucleotide repeats polymorphism in Chinese women with polycystic ovary syndrome. Endocrine 2008, 33: 165-70.
57. Bérubé D, Séralini GE, Gagné R, Hammond GL. Localization of the human sex hormone-binding globulin gene (SHBG) to the short arm of chromosome 17 (17p12>p13). Cytogenet Cell Genet 1990, 54: 65-7.
58. Pugeat M, Crave JC, Tournaire J, Forest MG. Clinical utility of sex hormone-binding globulin measurement. Horm Res 1996, 45: 148-55. (Pubitemid 26079699)
59. Hogeveen KN, Talikka M, Hammond GL. Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element an AIu sequence. J Biol Chem 2001, 276: 36383-90.
60. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA) in repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003, 88: 5976-80. (Pubitemid 38033081)
61. Cousin P, Calemard-Michel L, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 2004, 89: 917-24. (Pubitemid 38269911)
62. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The role of sex hormone-binding globulin and androgen receptor gene variants in the development of polycystic ovary syndrome. Hum Reprod 2008, 23: 693-6.
63. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome. Eur J Endocrinol 2008, 158: 861-5. (Pubitemid 351837375)
64. Chen MJ, Yang WES, Ho HN et al. Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS. Hum Reprod 2006, 21: 2266-71.
65. Balen AH. Hypersecretion of luteinizing hormone and the polycystic ovary syndrome. Hum Reprod 1993, 8 (Suppl 2): 123-8. (Pubitemid 23337190)
66. Okuda K, Yamada T, Imoto H, Komatsubara H, Sugimoto O. Antigenic alteration of an anomalous human luteinizing hormone caused by two chorionic gonadotropin-type amino-acid substitutions. Biochem Biophys Res Comm 1994, 200: 584-90. (Pubitemid 24183647)
67. Haavisto AM, Pettersson K, Bergendahl M, Virkamäki A, Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1995, 80: 1257-63.
68. Rajkhowa M, Talbot JA, Jones PW, et al. Prevalence of an immunological LH β-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Clin Endocrinol 1995, 43: 297-303.
69. Tapanainen JS, Koivunen R, Fauser BC, et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1999, 84: 1711-5. (Pubitemid 30644281)
70. Nilsson C, Pettersson K, Millar RP, Coerver KA, Matzuk MM, Huhtaniemi IT. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. Fertil Steril 1997, 67: 998-1004. (Pubitemid 27241889)
71. Elter K, Erel CT, Cine N et al. Role of the mutation Trp8->Arg and Ile15->Thr of the human luteinizing hormone β-subunit in women with polycystic ovary syndrome. Fertil Steril 1999, 71: 425-30. (Pubitemid 29094116)
72. Ramanujam LN, Liao WX, Roy AC, Loganath A, Goh HH, Ng SC. Association of molecular variants of luteinizing hormone with menstrual disorders. Clin Endocrinol (Oxf) 1999, 51: 243-6. (Pubitemid 29378911)
73. Roy AC, Liao WX, Chen Y, Arulkumaran S, Ratnam SS. Identification of seven novel mutations in LH β-subunit gene by SSCP. Mol Cell Biochem 1996, 165: 151-3. (Pubitemid 26421266)
74. Takahashi K, Karino K, Kanasaki H, et al. Influence of missense mutation and silent mutations in LH β-subunit gene in Japanese patients with ovulatory disorders. Eur J Hum Genet 2003, 11: 402-8. (Pubitemid 36656688)
75. Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001, 7: 405-10. (Pubitemid 32655326)
76. Urbanek M, Wu X, Vickery KR, et al. Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85: 4455-61. (Pubitemid 32157618)
77. Jones MR, Wilson SG, Mullin BH, Mead R, Watts GF, Stuckey BG. Polymorphism of the follistatin gene in polycystic ovary syndrome. Mol Hum Reprod 2007, 13: 237-41. (Pubitemid 46554741)
78. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996, 81: 3854-64.
79. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990, 32: 213-20. (Pubitemid 20039200)
80. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999, 20: 535-82. (Pubitemid 30647079)
81. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin terapy in polycystic ovarian syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43: 647-54. (Pubitemid 24145474)
82. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81: 3299-306. (Pubitemid 26296206)
83. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999, 48: 167-72. (Pubitemid 29072269)
84. Junien C, van Heyningen V. Report of the committee on the genetic constitution of chromosome 11. Cytogenet Cell Genet 1990, 55: 153-69.
85. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM regulates insulin transcription. Nat Genet 1995, 9: 293-8.
86. Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal C. The INS 5′ variable number tandem repeats is associated with IGF2 expression in humans. J Biol Chem 1998, 273: 14158-64. (Pubitemid 28319124)
87. Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997, 349: 1771-2. (Pubitemid 27252687)
88. Eaves IA, Bennett ST, Forster P, et al. Transmission ratio distortion at the INS-IGF2 VNTR. Nat Genet 1999, 22: 324-5. (Pubitemid 29369519)
89. Michelmore K, Ong K, Mason S, et al. Clinical features in women with polycystic ovaries: relationship to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001, 55: 439-46. (Pubitemid 32955480)
90. Calvo RM, Tellería D, Sancho J, San Millán JL, Escobar-Morreale HF. Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril 2002, 77: 666-8. (Pubitemid 34275340)
91. Vanková M, Vrbíková J, Hill M, Cinek O, Bendlová B. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Ann NY Acad Sci 2002, 967: 558-65. (Pubitemid 34721947)
92. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003, 361: 567-71. (Pubitemid 36207475)
93. Powell BL, Haddad L, Bennett A, et al. Analysis of multiple data sets reveals association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab 2005, 90: 2988-93. (Pubitemid 40686354)
94. Haller K, Laisk T, Peters M. VNTR I/I genotype of insulin gene is associated with the increase of follicle number independent from polycystic ovary syndrome. Acta Obstet Gynecol Scand 2007, 86: 726-32. (Pubitemid 46801779)
95. Goldfine ID. The insulin receptor: molecular biology and transmembran signaling. Endocr Rev 1987, 8: 235-55.
96. Moller DE, Flier JS. Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance). N Engl J Med 1988, 319: 1526-9. (Pubitemid 19003412)
97. Conway GS, Avey C, Rumsby G. The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinemia and polycystic ovary syndrome. Hum Reprod 1994, 9: 1681-3. (Pubitemid 24291083)
98. Sorbara LR, Tang Z, Cama A, et al. Absence of insulin receptor gene mutations in there insulin-resistant women with the polycystic ovary syndrome. Metabolism 1994, 43: 1568-74. (Pubitemid 24382710)
99. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O'Rahilly S, Clayton RN. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1996, 81: 1979-83. (Pubitemid 26152495)
100. Tucci S, Futterweit W, Concepcion ES, et al. Evidence of association of polycystic ovary syndrome in Caucasian women with marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001, 86: 446-9. (Pubitemid 32109833)
101. Urbanek M, Woodroffe A, Ewens KG, et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab 2005, 90: 6623-9. (Pubitemid 41759325)
102. Villuendas G, Escobar-Morreale HF, Tosi F, Sancho J, Moghetti P, San Millán JL. Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil Steril 2003, 79: 219-20. (Pubitemid 36071268)
103. Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002, 78: 1240-3. (Pubitemid 35469148)
104. Jin L, Zhu XM, Luo Q, Qian Y, Jin F, Huang HF. A novel SNP at exon 17 of INSR is associated with decreased insulin sensitivity in Chinese women with PCOS. Mol Hum Reprod 2006, 12: 151-5.
105. Lee EJ, Oh B, Lee JY, Kimm K, Lee SH, Baek KH. A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertil Steril 2008, 89: 1213-20. (Pubitemid 351671737)
106. Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab 2002, 87: 4085-7.
107. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994, 372: 746-54.
108. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 1998, 53: 119-38. (Pubitemid 128472739)
109. Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes 2001, 50 (Suppl 1): S140-5.
110. Jellema A, Zeegers MPA, Feskens EJM, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes: a meta-analysis of 27 studies. Diabetologie 2003, 46: 990-5. (Pubitemid 36961324)
111. Sir-Petermann T, Pérez-Bravo F, Angel B, Maliqueo M, Calvillan M, Palomino A. G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologie 2001, 44: 1200-1. (Pubitemid 32835516)
112. El Mkadem SA, Lautier C, Macari F, et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001, 50: 2164-8. (Pubitemid 33643687)
113. Dilek S, Ertunc D, Tok EC, Erdal EM, Aktas A. Association of the Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil Steril 2005, 84: 407-12. (Pubitemid 41125262)
114. Villuendas G, Botella-Carretero JI, Roldán B, Sancho J, Escobar-Morreale HF, San Millán JL. Polymorphism in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod 2005, 20: 3184-91. (Pubitemid 41662676)
115. Ertunc D, Tok EC, Aktas A, Erdal EM, Dilek S. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Hum Reprod 2005, 20: 1207-12. (Pubitemid 40790243)
116. Wiemsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin therapeutic and cellular mechanism. Drugs 1995, 58 (Suppl 1): 31-9. (Pubitemid 129758579)
117. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 e -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 4297-300.
118. Valdés P, Cerda A, Barrenechea C, Kehr M, Soto C, Salazar LA. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. Clin Chim Act 2008, 390: 63-6.
119. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26: 163-75.
120. Evans JC, Frayling TM, Cassell PG, et al. Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001, 69: 544-52. (Pubitemid 32777693)
121. Gonzales A, Abril E, Roca A, et al. Comment: CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 3971-6. (Pubitemid 34879556)
122. Wiltgen D, Furtado L, Kohek MB, Spritzer PM. CAPN10 UCSNP-43, UCSNP-19 and UCSNP-63 polymorphisms and metabolic syndrome in polycystic ovary syndrome. Gynecol Endocrinol 2007, 23: 173-8. (Pubitemid 46570217)
123. Haddad L, Evans JC, Gharani N, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 2606-10. (Pubitemid 34655321)
124. Escobar-Morreale HF, Peral B, Villuendas G, Calvo RM, Sancho J, San Millán JL. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil Steril 2002, 77: 581-7. (Pubitemid 34177215)
125. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89: 2548-56. (Pubitemid 38766330)
126. Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res 2001, 50: 439-59.
127. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334: 292-5. (Pubitemid 26033933)
128. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen S, Kontula K. No evidence for mutation of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod 2000, 6: 873-6.
129. Hara K, Boutin P, Mori Y, et al. Genetic variation at the gene encoding adiponectin is associated with an increased risk of the type 2 diabetes in the Japanese population. Diabetes 2002, 51: 1294. (Pubitemid 34438383)
130. Menzaghi C, Ercolino T, Di Paola R, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002, 51: 2306-12. (Pubitemid 34729040)
131. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (Exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002, 51: 37-41. (Pubitemid 34517977)
132. Hu FB, Doria A, Li T, et al. Genetic variation at the adiponectin locus and risk of type 2 diabetes in women. Diabetes 2004, 53: 209-13. (Pubitemid 38044717)
133. San Millán JL, Cortòn M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004, 89: 2640-6. (Pubitemid 38766343)
134. Panidis D, Kourtis A, Kukuvitis A, et al. Association of the T45G polymorphism in the exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Δ4-androstenedione. Hum Reprod 2004, 19: 1728-33. (Pubitemid 39144613)
135. Xita N, Georgiou I, Chatzikyriakidou A, et al. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem 2005, 51: 416-23. (Pubitemid 40175813)
136. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006, 21: 2257-65. (Pubitemid 44530598)
137. Elbrecht A, Chen Y, Cullinan CA et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Comm 1996, 224: 431-7. (Pubitemid 26268204)
138. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR-γ: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8: 1224-34.
139. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99: 2416-22. (Pubitemid 27227719)
140. Azziz R, Ehrmann D, Legro RS et al PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86: 1626-32. (Pubitemid 32374915)
141. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003, 79: 562-6. (Pubitemid 36293452)
142. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with Pro12Ala polymorphism in the PPARγ gene. J Clin Endocrinol Metab 2002, 87: 772-5. (Pubitemid 34158251)
143. Hahn S, Fingerhut A, Khomtsiv U et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005, 62: 573-9. (Pubitemid 40646724)
144. Korhonen S, Heinonen S, Hiltunen M, et al. Polymorphism in the peroxisome proliferator-actived receptor-γ gene in women with polycystic ovary syndrome. Hum Reprod 2003, 18: 540-3. (Pubitemid 36329321)
145. Yilmaz M, Ergün MA, Karakoç A, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol 2005, 21: 206-10. (Pubitemid 41769996)
146. Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006, 22: 336-42. (Pubitemid 43941411)
147. Orio F Jr, Matarese G, Di Biase S, et al. Exon 6 and 2 peroxisome proliferator-actived receptor-gamma polymorphism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 5887-92. (Pubitemid 38033068)
148. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003, 24: 278-301. (Pubitemid 36724371)
149. Diamanti-Kandarakis E, Piperi C, Spina J, et al. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006, 5: 17-34.
150. Möhlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004, 150: 525-32. (Pubitemid 38584704)
151. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999, 84: 272-8. (Pubitemid 29036713)
152. Fernández-Real JM, Brach M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998, 47: 1757-62. (Pubitemid 28476250)
153. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001, 86: 4398-405. (Pubitemid 32848565)
154. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995, 95: 2409-15.
155. Hotamisligil GS, Amer P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997, 46: 451-5. (Pubitemid 27090275)
156. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996, 271: 665-8. (Pubitemid 26052915)
157. Yudkin JS, Kumari M, Humphries SE, Mohamed-Alì V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148: 209-14. (Pubitemid 30064452)
158. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86: 2453-5. (Pubitemid 32545690)
159. Boulman N, Levy Y, Leiba R, et al. Increased C reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89: 2160-5. (Pubitemid 38619847)
160. Escobar-Morreale HF, Calvo RM, Sancho J, San Millán JL TNF-α and hyperandrogenism: a clinical, biochemical, and molecular genetic study. J Clin Endocrinol Metab 2001, 86: 3761-7. (Pubitemid 32755973)
161. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor α in normal-weight women with polycystic ovary syndrome. Metabolism 1999, 48: 437-41. (Pubitemid 29174220)
162. Sayin NC, Gücer F, Balkanli-Kaplan P, et al. Elevated serum TNF-α levels in normal-weight women with polycystic ovary syndrome. J Reprod Med 2003, 48: 165-70. (Pubitemid 36368954)
163. Amato G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003, 101: 1177-82. (Pubitemid 36694341)
164. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millán JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003, 11: 987-96. (Pubitemid 41137511)
165. Milner CR, Craig JE, Hussey ND, Norman RJ. No association between the -308 polymorphism in the tumor necrosis factors α (TNF-α) promoter region and polycystic ovaries. Mol Hum Reprod 1995, 5: 5-9. (Pubitemid 29045632)
166. Mao W, Yu L, Chen Y. Study on the relationship between a polymorphism of tumor necrosis factor-α gene and the pathogenesis of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2000, 35: 536-9.
167. Korhonen S, Romppanen E-L, Hiltunen M et al. Lack of association between C-850T polymorphism of the gene encoding tumor necrosis factor-α and polycystic ovary syndrome. Gynecol Endocrinol 2002, 16: 271-4. (Pubitemid 34988912)
168. Peral B, San Millán JL, Castello R, Moghetti P, Escobar-Morreale HF. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002, 87: 3977-83. (Pubitemid 34879557)
169. Villuendas G, San Millán JL, Sancho J, Escobar-Morreale HF. The -597G->A and 174G->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002, 87: 1134-41. (Pubitemid 36121078)
170. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005, 26: 251-82.
171. Knebel B, Janssen OE, Hahn S, et al. Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes 2008, 116: 481-6.
172. Erdogan M, Karadeniz M, Berdeli A, Alper G, Caglayan O, Yilmaz C. The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients. J Endocrinol Invest 2008, 31: 624-9.
173. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003, 24: 302-12. (Pubitemid 36724372)
174. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995, 92: 1851-5.
175. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004, 150: 793-8. (Pubitemid 38961652)
176. Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006, 55: 345-52. (Pubitemid 43234388)
177. Karadeniz M, Erdogan M, Zengi A et al. Polymophism of the interleukin-10 gene in polycystic ovary syndrome. Int J Immunogenet 2008, 35: 119-23. (Pubitemid 351347777)
178. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: A literature review including discussion of PPARγ. PPAR Res 2007, 2007: 49109.
179. Kahsar-Miller M, Azziz R. The developmentof the polycystic ovary syndrome: family history as a risk factor. Trends Endo Metab 1998, 9: 55-8. (Pubitemid 28207613)
180. Norman RJ, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine 2006, 30: 35-43. (Pubitemid 46020328)
181. Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996, 11: 1884-91. (Pubitemid 26381432)
182. Clark AM, Ledger W, Galletly C et al. Weight loss results in significant improvement in pregnancy and ovulation rates in oanovulatory obese women. Hum Reprod 1995, 10: 2702-12.
183. Roth LK, Taylor HS. Risk of smoking to reproductive health: assessment of women's knowledge. Am J Obstet Gynecol 2001, 184: 934-9. (Pubitemid 32368112)
184. Mishra GD, Dobson AJ, Schofield MJ. Cigarette smoking, menstrual symptoms and miscarriage among young women. Aust N Z J Public Health 2000, 24: 413-20.
185. Pattinson HA, Taylor PJ, Pattinson MH. The effect of cigarette smoking on ovarian function and early pregnancy outcome of in vitro fertilization treatment. Fertil Steril 1991, 55: 780-3.